Biomarkers of Aging (With a Clinical Potential in Oncology)

  • Joleen M. HubbardEmail author
Living reference work entry


Frailty is a result of underlying physiologic processes associated with aging that lead to poor functional reserve. With increasing degrees of frailty, the ability to recover from major stresses on the body such as cancer treatment becomes more difficult. Varying degrees of frailty can be subtle, which explains the difficulty of distinguishing which older adults will have excess toxicity from cancer therapy and ones will tolerate it well. Thus, a biomarker of aging would be a very useful tool to predict toxicity and functional decline with cancer treatment and guide treatment decisions for older patients.

Based on the large body of work in the field of aging research, several processes have emerged as hallmarks of the aging process. There is a decline of the lymphocyte component of the total leukocyte count. Systemic inflammation increases and likely contributes to age-related diseases. Telomere length decreases with cellular replication over time. Finally, repeated exposure to environmental stress results in cellular senescence. Researchers are now exploring biomarkers of these processes and their potential application in geriatric oncology. While they may not be pure aging biomarkers, they may be characterized as biomarkers of frailty that have the potential to identify patients at increased risk for adverse events, functional decline, and poorer survival related to cancer treatment. This chapter will discuss the characteristics of an aging biomarker, the various markers that have been investigated, and the evidence for the use of these biomarkers in older adults with cancer.


Biological marker Frailty Inflammatory markers Telomere length Immunosenescence 


  1. Atzmon G, Cho M, Cawthon RM, Budagov T, Katz M, Yang X, et al. Evolution in health and medicine Sackler colloquium: genetic variation in human telomerase is associated with telomere length in Ashkenazi centenarians. Proc Natl Acad Sci U S A. 2010;107(Suppl 1): 1710–7.PubMedCrossRefGoogle Scholar
  2. Bachelot T, Ray-Coquard I, Menetrier-Caux C, Rastkha M, Duc A, Blay JY. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J Cancer. 2003;88(11):1721–6.PubMedPubMedCentralCrossRefGoogle Scholar
  3. Baigrie RJ, Lamont PM, Kwiatkowski D, Dallman MJ, Morris PJ. Systemic cytokine response after major surgery. Br J Surg. 1992;79(8):757–60.PubMedCrossRefGoogle Scholar
  4. Bailur JK, Pawelec G, Hatse S, Brouwers B, Smeets A, Neven P, et al. Immune profiles of elderly breast cancer patients are altered by chemotherapy and relate to clinical frailty. Breast Cancer Res. 2017;19(1):20.PubMedPubMedCentralCrossRefGoogle Scholar
  5. Baker GT 3rd, Sprott RL. Biomarkers of aging. Exp Gerontol. 1988;23(4–5):223–39.PubMedCrossRefGoogle Scholar
  6. Bekaert S, De Meyer T, Van Oostveldt P. Telomere attrition as ageing biomarker. Anticancer Res. 2005;25(4): 3011–21.PubMedGoogle Scholar
  7. Blay JY, Chauvin F, Le Cesne A, Anglaret B, Bouhour D, Lasset C, et al. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol. 1996;14(2):636–43.PubMedCrossRefGoogle Scholar
  8. Brouwers B, Dalmasso B, Hatse S, Laenen A, Kenis C, Swerts E, et al. Biological ageing and frailty markers in breast cancer patients. Aging. 2015;7(5):319–33.PubMedPubMedCentralCrossRefGoogle Scholar
  9. Bruunsgaard H, Pedersen M, Pedersen BK. Aging and proinflammatory cytokines. Curr Opin Hematol. 2001;8(3):131–6.PubMedCrossRefGoogle Scholar
  10. Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell. 2005;120(4):513–22.PubMedCrossRefGoogle Scholar
  11. Carter RA, Wicks IP. Vascular cell adhesion molecule 1 (CD106): a multifaceted regulator of joint inflammation. Arthritis Rheum. 2001;44(5):985–94.PubMedCrossRefGoogle Scholar
  12. Cawthon RM, Smith KR, O'Brien E, Sivatchenko A, Kerber RA. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet. 2003;361(9355):393–5.PubMedCrossRefGoogle Scholar
  13. Cesari M, Penninx BW, Pahor M, Lauretani F, Corsi AM, Rhys Williams G, et al. Inflammatory markers and physical performance in older persons: the InCHIANTI study. J Gerontol A Biol Sci Med Sci. 2004;59(3): 242–8.PubMedCrossRefGoogle Scholar
  14. Cohen HJ, Harris T, Pieper CF. Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly. Am J Med. 2003;114(3):180–7.PubMedCrossRefGoogle Scholar
  15. Cohen HJ, Smith D, Sun CL, Tew W, Mohile SG, Owusu C, et al. Frailty as determined by a comprehensive geriatric assessment-derived deficit-accumulation index in older patients with cancer who receive chemotherapy. Cancer. 2016;122(24):3865–72.PubMedPubMedCentralCrossRefGoogle Scholar
  16. Collerton J, Martin-Ruiz C, Davies K, Hilkens CM, Isaacs J, Kolenda C, et al. Frailty and the role of inflammation, immunosenescence and cellular ageing in the very old: cross-sectional findings from the Newcastle 85+ Study. Mech Ageing Dev. 2012;133(6): 456–66.PubMedCrossRefGoogle Scholar
  17. Coppe JP, Patil CK, Rodier F, Sun Y, Munoz DP, Goldstein J, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008;6(12):2853–68.PubMedCrossRefGoogle Scholar
  18. de Lange T. Protection of mammalian telomeres. Oncogene. 2002;21(4):532–40.PubMedCrossRefGoogle Scholar
  19. De Martinis M, Franceschi C, Monti D, Ginaldi L. Inflammation markers predicting frailty and mortality in the elderly. Exp Mol Pathol. 2006;80(3):219–27.PubMedCrossRefGoogle Scholar
  20. de Saint-Hubert M, Jamart J, Morrhaye G, Martens HJ, Geenen V, Duy Vo TK, et al. Serum IL-6 and IGF-1 improve clinical prediction of functional decline after hospitalization in older patients. Aging Clin Exp Res. 2011;23(2):106–11.PubMedGoogle Scholar
  21. Demaria M, O’Leary MN, Chang J, Shao L, Liu S, Alimirah F, et al. Cellular senescence promotes adverse effects of chemotherapy and cancer relapse. Cancer Discov. 2017;7(2):165–76.PubMedCrossRefGoogle Scholar
  22. Ershler WB, Sun WH, Binkley N, Gravenstein S, Volk MJ, Kamoske G, et al. Interleukin-6 and aging: blood levels and mononuclear cell production increase with advancing age and in vitro production is modifiable by dietary restriction. Lymphokine Cytokine Res. 1993;12(4): 225–30.PubMedGoogle Scholar
  23. Extermann M, Boler I, Reich RR, Lyman GH, Brown RH, DeFelice J, et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2012;118(13):3377–86.PubMedCrossRefGoogle Scholar
  24. Fagiolo U, Cossarizza A, Scala E, Fanales-Belasio E, Ortolani C, Cozzi E, et al. Increased cytokine production in mononuclear cells of healthy elderly people. Eur J Immunol. 1993;23(9):2375–8.PubMedCrossRefGoogle Scholar
  25. Falandry C, Gilson E, Rudolph KL. Are aging biomarkers clinically relevant in oncogeriatrics? Crit Rev Oncol Hematol. 2013;85(3):257–65.PubMedCrossRefGoogle Scholar
  26. Falci C, Gianesin K, Sergi G, Giunco S, De Ronch I, Valpione S, et al. Immune senescence and cancer in elderly patients: results from an exploratory study. Exp Gerontol. 2013;48(12):1436–42.PubMedCrossRefGoogle Scholar
  27. Fernandez-Garrido J, Navarro-Martinez R, Buigues-Gonzalez C, Martinez-Martinez M, Ruiz-Ros V, Cauli O. The value of neutrophil and lymphocyte count in frail older women. Exp Gerontol. 2014;54: 35–41.PubMedCrossRefGoogle Scholar
  28. Ferrucci L, Harris TB, Guralnik JM, Tracy RP, Corti MC, Cohen HJ, et al. Serum IL-6 level and the development of disability in older persons. J Am Geriatr Soc. 1999;47(6):639–46.PubMedCrossRefGoogle Scholar
  29. Ferrucci L, Cavazzini C, Corsi A, Bartali B, Russo CR, Lauretani F, et al. Biomarkers of frailty in older persons. J Endocrinol Investig. 2002a;25(10 Suppl):10–5.Google Scholar
  30. Ferrucci L, Penninx BW, Volpato S, Harris TB, Bandeen-Roche K, Balfour J, et al. Change in muscle strength explains accelerated decline of physical function in older women with high interleukin-6 serum levels. J Am Geriatr Soc. 2002b;50(12):1947–54.PubMedCrossRefPubMedCentralGoogle Scholar
  31. Franceschi C, Capri M, Monti D, Giunta S, Olivieri F, Sevini F, et al. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev. 2007;128(1):92–105.PubMedCrossRefPubMedCentralGoogle Scholar
  32. Freund A, Orjalo AV, Desprez PY, Campisi J. Inflammatory networks during cellular senescence: causes and consequences. Trends Mol Med. 2010;16(5):238–46.PubMedPubMedCentralCrossRefGoogle Scholar
  33. Garg MB, Lincz LF, Adler K, Scorgie FE, Ackland SP, Sakoff JA. Predicting 5-fluorouracil toxicity in colorectal cancer patients from peripheral blood cell telomere length: a multivariate analysis. Br J Cancer. 2012;107(9):1525–33.PubMedPubMedCentralCrossRefGoogle Scholar
  34. Hubbard RE, O’Mahony MS, Savva GM, Calver BL, Woodhouse KW. Inflammation and frailty measures in older people. J Cell Mol Med. 2009;13(9B):3103–9.PubMedPubMedCentralCrossRefGoogle Scholar
  35. Huffman KM, Pieper CF, Kraus VB, Kraus WE, Fillenbaum GG, Cohen HJ. Relations of a marker of endothelial activation (s-VCAM) to function and mortality in community-dwelling older adults. J Gerontol A Biol Sci Med Sci. 2011;66(12):1369–75.PubMedCrossRefGoogle Scholar
  36. Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29:3457.PubMedPubMedCentralCrossRefGoogle Scholar
  37. Johnson TE. Recent results: biomarkers of aging. Exp Gerontol. 2006;41(12):1243–6.PubMedCrossRefGoogle Scholar
  38. Justice JN, Gregory H, Tchkonia T, LeBrasseur NK, Kirkland JL, Kritchevsky SB, et al. Cellular senescence biomarker p16INK4a+ cell burden in thigh adipose is associated with poor physical function in older women. J Gerontol A Biol Sci Med Sci. 2017;73:939.CrossRefGoogle Scholar
  39. Kanapuru B, Ershler WB. Inflammation, coagulation, and the pathway to frailty. Am J Med. 2009;122(7):605–13.PubMedPubMedCentralCrossRefGoogle Scholar
  40. Laird BJ, Kaasa S, McMillan DC, Fallon MT, Hjermstad MJ, Fayers P, et al. Prognostic factors in patients with advanced cancer: a comparison of clinicopathological factors and the development of an inflammation-based prognostic system. Clin Cancer Res. 2013;19(19): 5456–64.PubMedCrossRefGoogle Scholar
  41. Lawrence I, Bene M, Nacarelli T, Azar A, Cohen JZ, Torres C, et al. Correlations between age, functional status, and the senescence-associated proteins HMGB2 and p16(INK4a). Geroscience. 2018;40:193–9.PubMedPubMedCentralCrossRefGoogle Scholar
  42. Leng SX, Xue QL, Tian J, Walston JD, Fried LP. Inflammation and frailty in older women. J Am Geriatr Soc. 2007;55(6):864–71.PubMedCrossRefGoogle Scholar
  43. Li W, Tao L, Zhang L, Xiu D. Prognostic role of lymphocyte to monocyte ratio for patients with pancreatic cancer: a systematic review and meta-analysis. Onco Targets Ther. 2017;10:3391–7.PubMedPubMedCentralCrossRefGoogle Scholar
  44. Liu Y, Sanoff HK, Cho H, Burd CE, Torrice C, Ibrahim JG, et al. Expression of p16(INK4a) in peripheral blood T-cells is a biomarker of human aging. Aging Cell. 2009;8(4):439–48.PubMedPubMedCentralCrossRefGoogle Scholar
  45. Lorenzi M, Bonassi S, Lorenzi T, Giovannini S, Bernabei R, Onder G. A review of telomere length in sarcopenia and frailty. Biogerontology. 2018;19: 209–21.PubMedCrossRefGoogle Scholar
  46. McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39(5):534–40.PubMedCrossRefGoogle Scholar
  47. Mishra MV, Showalter TN, Dicker AP. Biomarkers of aging and radiation therapy tailored to the elderly: future of the field. Semin Radiat Oncol. 2012;22(4): 334–8.PubMedCrossRefGoogle Scholar
  48. Nishijima TF, Muss HB, Shachar SS, Tamura K, Takamatsu Y. Prognostic value of lymphocyte-to-monocyte ratio in patients with solid tumors: a systematic review and meta-analysis. Cancer Treat Rev. 2015;41(10):971–8.PubMedCrossRefGoogle Scholar
  49. Nishijima TF, Deal AM, Williams GR, Guerard EJ, Nyrop KA, Muss HB. Frailty and inflammatory markers in older adults with cancer. Aging. 2017;9(3): 650–64.PubMedPubMedCentralCrossRefGoogle Scholar
  50. Njajou OT, Hsueh WC, Blackburn EH, Newman AB, Wu SH, Li R, et al. Association between telomere length, specific causes of death, and years of healthy life in health, aging, and body composition, a population-based cohort study. J Gerontol A Biol Sci Med Sci. 2009;64(8):860–4.PubMedCrossRefGoogle Scholar
  51. Pallis AG, et al. Evaluating the physiological reserves of older patients with cancer: the value of potential biomarkers of aging? J Geriatr Oncol. 2013;5:204.PubMedCrossRefGoogle Scholar
  52. Pallis AG, Hatse S, Brouwers B, Pawelec G, Falandry C, Wedding U, et al. Evaluating the physiological reserves of older patients with cancer: the value of potential biomarkers of aging? J Geriatr Oncol. 2014;5(2): 204–18.PubMedCrossRefGoogle Scholar
  53. Pawelec G, Solana R. Immunosenescence. Immunol Today. 1997;18(11):514–6.PubMedCrossRefGoogle Scholar
  54. Pieper CF, Rao KM, Currie MS, Harris TB, Cohen HJ. Age, functional status, and racial differences in plasma D-dimer levels in community-dwelling elderly persons. J Gerontol A Biol Sci Med Sci. 2000;55(11):M649–57.PubMedCrossRefGoogle Scholar
  55. Pooley KA, Sandhu MS, Tyrer J, Shah M, Driver KE, Luben RN, et al. Telomere length in prospective and retrospective cancer case-control studies. Cancer Res. 2010;70(8):3170–6.PubMedPubMedCentralCrossRefGoogle Scholar
  56. Prescott J, Wentzensen IM, Savage SA, De Vivo I. Epidemiologic evidence for a role of telomere dysfunction in cancer etiology. Mutat Res. 2012;730(1–2): 75–84.PubMedCrossRefGoogle Scholar
  57. Puts MT, Visser M, Twisk JW, Deeg DJ, Lips P. Endocrine and inflammatory markers as predictors of frailty. Clin Endocrinol. 2005;63(4):403–11.CrossRefGoogle Scholar
  58. Quintela-Fandino M, Soberon N, Lluch A, Manso L, Calvo I, Cortes J, et al. Critically short telomeres and toxicity of chemotherapy in early breast cancer. Oncotarget. 2017;8(13):21472–82.PubMedPubMedCentralCrossRefGoogle Scholar
  59. Ray-Coquard I, Borg C, Bachelot T, Sebban C, Philip I, Clapisson G, et al. Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. Br J Cancer. 2003;88(2):181–6.PubMedPubMedCentralCrossRefGoogle Scholar
  60. Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 2009;69(13): 5383–91.PubMedPubMedCentralCrossRefGoogle Scholar
  61. Ressler S, Bartkova J, Niederegger H, Bartek J, Scharffetter-Kochanek K, Jansen-Durr P, et al. p16INK4A is a robust in vivo biomarker of cellular aging in human skin. Aging Cell. 2006;5(5):379–89.PubMedCrossRefGoogle Scholar
  62. Reuben DB, Cheh AI, Harris TB, Ferrucci L, Rowe JW, Tracy RP, et al. Peripheral blood markers of inflammation predict mortality and functional decline in high-functioning community-dwelling older persons. J Am Geriatr Soc. 2002;50(4):638–44.PubMedCrossRefGoogle Scholar
  63. Robson SC, Shephard EG, Kirsch RE. Fibrin degradation product D-dimer induces the synthesis and release of biologically active IL-1 beta, IL-6 and plasminogen activator inhibitors from monocytes in vitro. Br J Haematol. 1994;86(2):322–6.PubMedCrossRefGoogle Scholar
  64. Romagosa C, Simonetti S, Lopez-Vicente L, Mazo A, Lleonart ME, Castellvi J, et al. p16(Ink4a) overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors. Oncogene. 2011;30(18):2087–97.PubMedCrossRefGoogle Scholar
  65. Ronning B, Wyller TB, Seljeflot I, Jordhoy MS, Skovlund E, Nesbakken A, et al. Frailty measures, inflammatory biomarkers and post-operative complications in older surgical patients. Age Ageing. 2010;39(6):758–61.PubMedCrossRefGoogle Scholar
  66. Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 2010;6(1): 149–63.PubMedCrossRefGoogle Scholar
  67. Saito K, Kihara K. C-reactive protein as a biomarker for urological cancers. Nat Rev Urol. 2011;8(12):659–66.PubMedCrossRefGoogle Scholar
  68. Sanoff HK, Deal AM, Krishnamurthy J, Torrice C, Dillon P, Sorrentino J, et al. Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer. J Natl Cancer Inst. 2014;106(4):dju057.PubMedPubMedCentralCrossRefGoogle Scholar
  69. Saum KU, Dieffenbach AK, Muezzinler A, Muller H, Holleczek B, Stegmaier C, et al. Frailty and telomere length: cross-sectional analysis in 3537 older adults from the ESTHER cohort. Exp Gerontol. 2014;58: 250–5.PubMedCrossRefGoogle Scholar
  70. Sharma R, Zucknick M, London R, Kacevska M, Liddle C, Clarke SJ. Systemic inflammatory response predicts prognosis in patients with advanced-stage colorectal cancer. Clin Colorectal Cancer. 2008;7(5):331–7.PubMedCrossRefGoogle Scholar
  71. Sieburg HB, Cho RH, Dykstra B, Uchida N, Eaves CJ, Muller-Sieburg CE. The hematopoietic stem compartment consists of a limited number of discrete stem cell subsets. Blood. 2006;107(6):2311–6.PubMedPubMedCentralCrossRefGoogle Scholar
  72. Simm A, Nass N, Bartling B, Hofmann B, Silber RE, Navarrete Santos A. Potential biomarkers of ageing. Biol Chem. 2008;389(3):257–65.PubMedCrossRefGoogle Scholar
  73. Sindermann J, Kruse A, Frercks HJ, Schutz RM, Kirchner H. Investigations of the lymphokine system in elderly individuals. Mech Ageing Dev. 1993;70(1–2):149–59.PubMedCrossRefGoogle Scholar
  74. Song Z, von Figura G, Liu Y, Kraus JM, Torrice C, Dillon P, et al. Lifestyle impacts on the aging-associated expression of biomarkers of DNA damage and telomere dysfunction in human blood. Aging Cell. 2010;9(4):607–15.PubMedPubMedCentralCrossRefGoogle Scholar
  75. Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocana A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014a;106(6):dju124.PubMedCrossRefPubMedCentralGoogle Scholar
  76. Templeton AJ, Ace O, McNamara MG, Al-Mubarak M, Vera-Badillo FE, Hermanns T, et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomark Prev. 2014b;23(7):1204–12.CrossRefGoogle Scholar
  77. Tham T, Olson C, Khaymovich J, Herman SW, Costantino PD. The lymphocyte-to-monocyte ratio as a prognostic indicator in head and neck cancer: a systematic review and meta-analysis. Eur Arch Otorhinolaryngol. 2018;275:1663.PubMedCrossRefPubMedCentralGoogle Scholar
  78. Tsygankov D, Liu Y, Sanoff HK, Sharpless NE, Elston TC. A quantitative model for age-dependent expression of the p16INK4a tumor suppressor. Proc Natl Acad Sci U S A. 2009;106(39):16562–7.PubMedPubMedCentralCrossRefGoogle Scholar
  79. Vasto S, Candore G, Balistreri CR, Caruso M, Colonna-Romano G, Grimaldi MP, et al. Inflammatory networks in ageing, age-related diseases and longevity. Mech Ageing Dev. 2007;128(1):83–91.PubMedCrossRefGoogle Scholar
  80. Waaijer ME, Westendorp RG, Goldeck D, Gunn DA, Pawelec G, Stijntjes M, et al. Assessment of health status by molecular measures in adults ranging from middle-aged to old: ready for clinical use? Exp Gerontol. 2017;87(Pt B):175–81.PubMedCrossRefGoogle Scholar
  81. Walston J, McBurnie MA, Newman A, Tracy RP, Kop WJ, Hirsch CH, et al. Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: results from the Cardiovascular Health Study. Arch Intern Med. 2002;162(20): 2333–41.PubMedCrossRefGoogle Scholar
  82. Wang J, Sun Q, Morita Y, Jiang H, Gross A, Lechel A, et al. A differentiation checkpoint limits hematopoietic stem cell self-renewal in response to DNA damage. Cell. 2012;148(5):1001–14.PubMedCrossRefGoogle Scholar
  83. Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen ML, Extermann M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol. 2014;32(24):2595–603.PubMedPubMedCentralCrossRefGoogle Scholar
  84. Willeit P, Willeit J, Mayr A, Weger S, Oberhollenzer F, Brandstatter A, et al. Telomere length and risk of incident cancer and cancer mortality. JAMA. 2010;304(1): 69–75.PubMedCrossRefGoogle Scholar
  85. Wirtz DC, Heller KD, Miltner O, Zilkens KW, Wolff JM. Interleukin-6: a potential inflammatory marker after total joint replacement. Int Orthop. 2000;24(4):194–6.PubMedPubMedCentralCrossRefGoogle Scholar
  86. Yao X, Li H, Leng SX. Inflammation and immune system alterations in frailty. Clin Geriatr Med. 2011;27(1): 79–87.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Mayo ClinicRochesterUSA

Section editors and affiliations

  • William Dale
    • 1
  1. 1.Department of Supportive Care MedicineCity of Hope Duarte - Comprehensive Cancer CenterDuarteUSA

Personalised recommendations